

RENALYTIX AI

Proposed dual-listing on Nasdaq

May 18, 2020

Download [full announcement](#)

Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has confidentially submitted a draft registration statement on Form F-1 with the Securities and Exchange Commission (the “SEC”) relating to a proposed dual-listing and public offering of American Depositary Shares, each of which will represent one or a number of the Company’s ordinary shares, on the Nasdaq Stock Market (the “Offering”).

The number of securities to be offered and the price for the proposed Offering have not yet been determined. The Offering is expected to commence after the SEC completes its review process, subject to market and other conditions. Shareholders and potential investors should note that the potential Offering may or may not proceed.

This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the “Securities Act”). This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.

Enquiries

Renalytix AI plc

James McCullough, CEO

www.renalytixai.com

Via Walbrook PR

Stifel (Nominated Adviser & Joint Broker)

Alex Price / Nicholas Moore

Tel: 020 7710 7600

Walbrook PR Limited

Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780
renalytix@walbrookpr.com
Mob: 07980 541 893
07584 391 303

About Kidney Disease

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control estimates there that 15% of United States adults or 37 million people currently have kidney disease. It is reported that 9 out of 10 adults with chronic kidney disease do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a “silent killer” because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day 13 patients die in the United States while waiting for a kidney transplant.

*<https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html>

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical *in vitro* diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com